Rigel Pharmaceuticals | RIGL - Cost Of Sales

Stock Price
29.64
Daily Change
0.01 0.03%
Monthly
-13.21%
Yearly
50.46%
Q1 Forecast
33.68

Rigel Pharmaceuticals reported $8.03M in Cost of Sales for its fiscal quarter ending in September of 2024.





Cost Of Sales Change Date
Agenus USD 137K 19K Mar/2025
Amgen USD 1.79B 128M Dec/2025
Anika Therapeutics USD 11.49M 35.48M Mar/2025
AstraZeneca USD 3.27B 471M Dec/2025
BioMarin Pharmaceutical USD 161.56M 16.62M Dec/2025
Bristol-Myers Squibb USD 4.92B 657M Dec/2025
Celldex Therapeutics USD 54.2M 8.94M Jun/2025
Daiichi Sankyo JPY 118.28B 37.7B Dec/2025
Eli Lilly USD 3.37B 363.7M Dec/2025
Halozyme Therapeutics USD 102.15M 29.14M Dec/2025
Heron Therapeutics USD 9.46M 1.61M Sep/2024
Intrexon USD 1.01M 344K Jun/2024
Ionis Pharmaceuticals USD 8M 5.66M Dec/2025
Karyopharm Therapeutics USD 37.43M 2.41M Sep/2024
Ligand Pharmaceuticals USD 11.9M 733K Sep/2025
MacroGenics USD 44.3M 5.4M Sep/2025
Neurocrine Biosciences USD 17.6M 246.4M Dec/2025
Pfizer USD 6.29B 2.12B Dec/2025
Regeneron Pharmaceuticals USD 584.6M 63M Dec/2025
Rigel Pharmaceuticals USD 8.03M 5.22M Sep/2024
Sangamo BioSciences 2.42M 1.11M Jun/2024
Ultragenyx Pharmaceutical USD 29M 1.01M Dec/2025
Veracyte USD 39.28M 1.93M Dec/2025